4th Annual Monoclonal Antibodies Conference

4th Annual Monoclonal Antibodies Conference
27th - 28th March 2008, etc.venues Bonhill House, London, UK
Achieving faster development, production and modification of antibody-based therapeutics

Key Speakers

Dr Valerie E. Quarmby Associate Director, Bioanalytical Research and Development, Genentech
Dr David Lowe, Head of Display Technology, MedImmune
Dr Robert J. Lutz, Executive Director, Preclinical Development, ImmunoGen
Dr Henning Dierks, Strategic Marketing Manager, BioProcess, GE Healthcare
Philippe Stas, Chief Operating Officer, AlgoNomics
Tobias Raum Director, Human Antibody Technology, Micromet
Professor Andrew J. R. Porter, Chair in Molecular & Cell Biology, University of Aberdeen
Dr Uwe Gottschalk, Group Vice President of Purifi cation Technologies, Sartorius Stedim
Dr Matthew Baker, Chief Scientifi c Officer, Antitope
Dr Martyn Robinson, VP - Antibody Project Biology, UCB Celltech
Professor Herta Steinkellner, Insitute of Applied Genetics and Cell biology, BOKU-Wien
Rebecca Lawrence, Senior Associate, Powell Gilbert

At an estimated worldwide market value of $24 billion in 2007, monoclonal antibodies (mAbs) for therapeutic use are poised to reach an estimated value of $47 billion by 2012 for a CAGR of 14%. (BCC Research, 2007)
Dear Colleague,
Monoclonal antibody therapies have been posting the fastest growth within the protein therapeutics market easily outstripping the growth rate of 0.6% in the more traditional, small molecules market. With key products forecast to record peak sales growth and the launch of new products, this rapid expansion is set to continue. In addition to occupying a sector of the market that is insulated from generic competition, mAbs have the advantage of primarily addressing high unmet need therapy areas such as oncology and AIID. Hundreds of monoclonal antibodies are presently undergoing various stages of clinical development. Many in the industry are utilizing ex vivo libraries and development of transgenic mice which generate antibodies with a human protein sequence instead of a mouse protein sequence, thus allowing for the development of mAbs with higher human composition. Alliances between pharmaceutical and biotech companies are a key driver of the current mAb market. With big pharma backing smaller biotech companies in their research and clinical programs, and thus funding vital manufacturing facilities, there is little reason why the mAb market will not continue to flourish. Delivered by a panel of expert speakers Visiongain’s 4th Annual Monoclonal Antibodies in Therapeutics, will provide the ideal forum for leading companies, and those with emerging products or technologies to collaborate and exchange ideas. This two- day programme will examine strategies employed by biotechnology companies and pharmaceutical firms to develop and market products in this highly exciting market sector, and discuss the advantages and limitations of antibody-based products, patent issues and applicability.

Why you should attend?

Assess the strategic decisions which have been implemented by key mAb market players
Examine the current technologies underlying the mAb market and discuss the effects of new technologies on this market
Learn about recent advances in therapeutic applications Examine the market potential of promising drugs under development
Address challenges to the research, production modification of mAbs
Develop new antibody therapies with strong effi cacy and good side effect profiles
Form strategic alliances and improve on existing partnerships
Analyse the current patent landscape and discuss future IP issues
Discover new directions in antibody research
I look forward to seeing you there
Yours sincerely,

Andrea Charles
Senior Conference Producer
Pharmaceutical Division

For more information kindly visit: http://www.bharatbook.com/seminars/4th-Annual-Monoclonal-Antibodies-Conference.asp